Elizabeth Lutas
Internal Medicine · Bronx, NYNPI 1437282605
Payments from drug & device makers
Across 145 payments — averaging $23.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$859
- Gilead$416
- Viiv Healthcare Company$311
- Otsuka America Pharmaceutical, Inc.$103
- Merck$67
- plus $345 from 12 others
What the payments were for
- Food & beverage$3,463100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 56 | $1,362 |
| Neurocrine Biosciences, Inc. | 36 | $859 |
| Gilead | 15 | $416 |
| Viiv Healthcare Company | 15 | $311 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Merck | 3 | $67 |
| Theratechnologies Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Novo Nordisk | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 1 | $37 |
| AbbVie | 1 | $29 |
| Mannkind Corporation | 1 | $25 |
| Indivior Inc. | 1 | $24 |
| GSK | 1 | $23 |
| Napo Pharmaceuticals Inc | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $16 |
| Orexo US, Inc. | 1 | $14 |
How this compares
$3,463 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $56,742 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $46,980 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,208 |
| EvotazAtazanavir Sulfate/Cobicistat | 13 | $19,834 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,499 |
| EliquisApixaban | 13 | $7,457 |
| JanuviaSitagliptin Phosphate | 11 | $5,728 |
| Epinephrine | 15 | $4,467 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $2,058 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $1,771 |
| Midodrine Hcl | 11 | $1,136 |
| Diltiazem 12hr ErDiltiazem Hcl | 11 | $827 |
| Atorvastatin Calcium | 97 | $653 |
| Gabapentin | 62 | $592 |
| Ammonium Lactate | 20 | $474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Descovy | $416 | $74,18825 claims |
| E.r. Squibb & Sons, L.L.C.Evotaz | $37 | $19,83413 claims |
| GSKTrelegy Ellipta | $23 | $7,49912 claims |
| MerckJanuvia | $67 | $5,72811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.